BMC Cardiovascular Disorders

Table 3 Association of patient characteristics to the delays in multivariable linear regression

From: Trends in treatment delays for patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

			HUS-STEMI I						HUS-STEMI II
	EMS delay		Door-to-balloon		System delay		EMS delay		Door-to-balloon		System delay
	Beta	p	Beta	p	Beta	p	Beta	p	Beta	p	Beta	p
Age	0.082	0.394	0.132	0.235	0.139	0.184	-0.007	0.915	-0.028	0.705	-0.039	0.596
Sex	-0.048	0.564	-0.073	0.445	-0.034	0.709	-0.036	0.555	0.010	0.884	0.008	0.899
Smoking	0.095	0.308	0.112	0.295	0.169	0.096	-0.085	0.192	0.019	0.788	-0.050	0.489
Post-MI	-0.198	0.025	0.058	0.566	-0.163	0.091	0.089	0.166	0.047	0.497	0.090	0.193
Post-stroke	0.184	0.030	-0.059	0.545	0.164	0.073	-0.072	0.250	-0.066	0.331	-0.089	0.188
Diabetes	0.152	0.058	0.070	0.459	0.134	0.134	-0.064	0.316	0.003	0.966	-0.003	0.963
Hypertension	-0.048	0.565	-0.002	0.987	-0.046	0.612	0.037	0.586	-0.076	0.295	-0.084	0.248
Dyslipidemia	-0.034	0.686	0.097	0.317	0.032	0.725	-0.012	0.851	0.174	0.016	0.149	0.038
Anterior infarct	-0.092	0.235	-0.028	0.753	-0.026	0.761	0.047	0.433	-0.014	0.831	0.026	0.689
Killip class 2--4	-0.126	0.116	-0.056	0.541	-0.084	0.327	-0.052	0.404	0.141	0.039	0.073	0.278
Regular hours	-0.102	0.202	-0.003	0.974	-0.097	0.260	-0.011	0.851	-0.204	0.002	-0.167	0.010
Patient related delay > 120 min	0.215	0.101	0.059	0.702	0.321	0.027	0.159	0.099	0.017	0.877	0.063	0.556
New treatment protocol							-0.178	0.003	-0.089	0.174	-0.18	0.006

The new treatment protocol in the HUS-STEMI II dataset refers to the use of antithrombotic drug combination enoxaparine-prasugrel-bivalirudin. MI, myocardial infarction.

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com